Raf inhibition causes extensive multiple tissue hyperplasia and urinary bladder neoplasia in the rat

Toxicologic Pathology

Volumn 39, Issue 5, 2011, Pages 809-822

  Wisler, John A ^a   Afshari, Cynthia ^a   Fielden, Mark ^a   Zimmermann, Cameron ^a   Taylor, Scott ^a   Carnahan, Josette ^a   Vonderfecht, Steven ^a  

^a AMGEN INC   (United States)

Author keywords

B Raf; carcinoma; hyperplasia; urinary bladder

Indexed keywords

B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER TUMOR; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME SYNTHESIS; EPITHELIUM HYPERPLASIA; FEMALE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; SIGNAL TRANSDUCTION;

ANIMALS; CELL PROLIFERATION; CLUSTER ANALYSIS; FEMALE; HISTOCYTOCHEMISTRY; HYPERPLASIA; MALE; MAP KINASE SIGNALING SYSTEM; MUTATION; MYOCARDIUM; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RATS; RATS, SPRAGUE-DAWLEY; SCIATIC NERVE; STOMACH; TISSUE DISTRIBUTION; TOXICITY TESTS, CHRONIC; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

RATTUS;

EID: 79961044242     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311410442     Document Type: Article

References (41)

1. Boutros T., Chevet E., Petrakos P. Mitogen-activated protein (MAP) Kinase/map kinase phosphatase regulation: Roles in cell growth, death, and cancer. Pharmacol Rev. 2008 ; 60: 261-310
2. Brower V. BRAF inhibitors: Research accelerates in wake of positive findings. Journal of the National Cancer Institute. 2010 ; 102: 214-5
3. Butterworth B. Consideration of both genotoxic and nongenotoxic mechanisms in predicting carcinogenic potential. Mutat Res. 1990 ; 239: 117-32
4. Carnahan J., Beltran P., Babij C., Fernando S., Vonderfecht S., Wisler J., Le Q., Rose M., Nagapudi K., Smith A., Kim J., Broome M., Radnisky R., Kendall R., Burgess T. Proceedings of the 101st Annual Meeting of the American Association for Cancer Research. DC: Washington ; 2010 :
5. Carnahan J., Beltran P. J., Babij C., Le Q., Rose M. J., Vonderfecht S., Kim J. L., Smith A. L., Nagapudi K., Broome M. A., Fernando M., Kha H., Belmontes B., Radinsky R., Kendall R., Burgess T. L. Selective and potent Raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth. Mol Cancer Ther. 2010 ; 9: 2399-410
6. Cohen S. Urinary bladder carcinogenesis. Toxicologic Pathology. 1998 ; 26: 121-7 (Pubitemid 28100696)
7. Cohen S., Wanibuchi H., Fukushima S. Handbook of Toxicologic Pathology. 2002 ). Lower urinary tract. In Handbook of Toxicologic Pathology (HaschekW. M. RousseauxC. G.WalligM. A., eds.), 2nd Edition, Vol. 2, pp. 337-62. Academic Press, San Diego, CA.
8. Haschek W. M. Rousseaux C. G. Wallig M. A., ed. San Diego, CA: Academic Press ; 2002: 337-62.
9. Cohen S. Effects of PPAR? and combined agonists on the urinary tract of rats and other species. Toxicol Sci. 2005 ; 87 (2). 322-7 (Pubitemid 41300679)
10. Cohen S. Thresholds in genotoxicity and carcinogenicity: urinary bladder carcinogenesis. Gene and Environ. 2008 ; 30 (4). 132-8
11. Cohen S., Ohnishi T., Arnold L. L., Le X. C. Arsenic-induced bladder cancer in an animal model. Toxicology & Applied Pharmacology. 2007 ; 222: 258-63 (Pubitemid 47198272)
12. Davies H., Bignell G. R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M. J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B. A., Cooper C., Shipley S., Hargrave D., Pritchard-Jones K., Maitland N., Chenevix-Trench G., Riggins G. J., Bigner D. D., Palmieri G., Cossu C., Flanagan A., Nicholson A., Ho J. W. C., Leung S. Y., Yuen S. T., Weber B. L., Seigler H. F., Darrow T. L., Paterson H., Marais R., Marshall C. J., Wooster R., Stratton M. R., Futreal P. A. Mutations of the BRAF gene in human cancer. Nature. 2002 ; 417: 949-54 (Pubitemid 34716871)
13. Eblin K., Bredfeldt T. G., Buffington S., Gandolfi A. J. Mitogenic signal transduction caused by monomethylarsonous acid in human bladder cells: role in arsenic-induced carcinogenesis. Toxicological Sciences. 2007 ; 95: 321-30 (Pubitemid 46152604)
14. Flaherty K., Puzanov I., Kim K., Ribas A., McAuthur G., Sosman A., O'Dwyer P., Lee R., Grippo J., Nolop K., Chapman P. Inhibition of mutated, actiated BRAF in metastatic melanoma. NEJM. 2010 ; 363: 809-19
15. Gautier L., Cope L., Bolstad B. M., Irizarry R. A. affy: Analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004 ; 20: 307-15 (Pubitemid 38262761)
16. Giknis M., Clifford C. Charles River Laboratories. MI: Portage ; 2001 :
17. Greenfield R., Ellwein L., Cohen S. A general probabilistic model of carcinogenesis: analysis of experimental urinary bladder cancer. Carcinogenesis. 1984 ; 5 (4). 437-45 (Pubitemid 14126706)
18. Haagenson K., Wu G. S. Mitogen activated protein kinase phosphatases and cancer. Cancer Biology & Therapy. 2010 ; 9: 335-8
19. Harrisingh M., Perez-Nadales E., Parkinson D., Malcolm D., Mudge A., Lloyd A. The Ras/ Raf/ ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J. 2004 ; 23: 3061-71 (Pubitemid 39093600)
20. Hatzivassiliou G., Song K., Yen I., Brandhuber B. J., Anderson D. J., Alvarado R., Ludlam M. J. C., Stokoe D., Gloor S. L., Vigers G., Morales T., Aliagas I., Liu B., Sideris S., Hoeflich K. P., Jaiswal B. S., Seshagiri S., Koeppen H., Belvin M., Friedman L. S., Malek S. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature. 2010 ; 464: 431-NIL132
21. Heidorn S. J., Milagre C., Whittaker S., Nourry A., Niculescu-Duvas I., Dhomen N., Hussain J., Reis-Filho J. S., Springer C. J., Pritchard C., Marais R. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 2010 ; 140 (2). 209-21
22. Hoeflich K., Herter S., Tien J., Wong L., Berry L., Chan J., O'Brien C., Modrusan Z., Seshagiri S., Lackner M., Stern H., Choo E., Murray L., Friedman L. S., Belvin M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009 ; 69: 3032-51
23. Keay S., Zhang C. O., Kagen D. I., Hise M. K., Jacobs S. C., Hebel J. R., Gordon D., Whitmore K., Bodison S., Warren J. W. Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. Journal of Urology. 1997 ; 158: 1983-8 (Pubitemid 27433199)
24. Kendziorski C., Newton M. A., Lan H., Gould M. N. On parametric empirical Bayes methods for comparing multiple groups using replicated gene expression profiles. Statistics in Medicine. 2003 ; 22: 3899-914 (Pubitemid 38008708)
25. Kumar B., Sinclair J., Khandrika L., Koul S., Wilson S., Koul H. Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. International Journal of Oncology. 2009 ; 34: 1557-1564
26. Lima B., Van der Laan J. W. Mechanisms of nongenotoxic carcinogenesis and assessment of the human hazard. Regulatory Toxicology & Pharmacology. 2000 ; 32: 135-43
27. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a γ-dominant PPAR α/γ agonist: Lack of evidence for urolithiasis as an inciting event. Toxicologic Pathology. 2008 ; 36: 218-31 (Pubitemid 351545780)
28. Luis N., Lopez-Knowles E., Real F. X. Molecular biology of bladder cancer. Clinical and Translational Oncology. 2007 ; 9 (1). 5-12
29. Luster M., Simeonova P. P. Arsenic and urinary bladder cell proliferation. Toxicology & Applied Pharmacology. 2004 ; 198: 419-23 (Pubitemid 38969971)
30. Marais R., Light Y., Paterson H. F., Mason C. S., Marshall C. J. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic Ras and tyrosine kinases. Journal of Biological Chemistry. 1997 ; 272: 4378-83
31. Mohr U. Lyon, France: International Agency for Research on Cancer ; 1992: 31-32.
32. Papin C., Denouel A., Calothy G., Eychene A. Identification of signalling proteins interacting with b-raf in the yeast two-hybrid system. Oncogene. 1996 ; 12: 2213-21 (Pubitemid 26168430)
33. Pogribny I., Rusyn I., Beland F. Epigenetic aspects of genotoxic and non-genotoxic hepatogenesis. Environ Mol Mutagen. 2008 ; 49 (1). 9-15 (Pubitemid 351293008)
34. Poulikakos P., Zhang C., Bollag G., Shokat K. M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature. 2010 ; 464: 427
35. Rakitsky V., Koblyakov V., Turusove V. Nongenotoxic (epigenetic) carcinogens: pesticides as an example. A critical review. Teratogen Carcinogen Mutagen. 2000 ; 20: 229-40
36. Romih R., Jezernik K., Masera A. Uroplakins and cytokeratins in the regenerating rat urothelium after sodium saccharin treatment. Histochemistry & Cell Biology. 1998 ; 109: 263-9 (Pubitemid 28114291)
37. Rose B., Force T., Wang Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol Rev. 2010 ; 90: 1507-1546
38. Smith A., DeMorin F. F., Paras N. A., Huang Q., Petkus J. K., Doherty E. M., Nixey T., Kim J. L., Whittington D. A., Epstein L. F., Lee M. R., Rose M. J., Babij C., Fernando M., Hess K., Le Q., Beltran P., Carnahan J. Selective inhibitors of the mutant B-Raf pathway: Discovery of a potent and orally bioavailable aminoisoquinoline. Journal of Medicinal Chemistry. 2009 ; 52: 6189-92
39. Verani P., Romih R., Jezernik K. What determines differentiation of urothelial umbrella cells?. European Journal of Cell Biology. 2004 ; 83: 27-34 (Pubitemid 38455604)
40. Wan P., Garnett M., Roe S., Lee S., Niculescu-Duvaz D., Good V. Jones C., Marshall C., Springer C., Barford D., Marais R. Mechanism of action of the RAF-ERK signaling pathway by oncogenic mutation of B-RAF. Cell. 2004 ; 116: 855-67 (Pubitemid 38410730)
41. Xu J., Liu X., Jiang Y., Chu L., Hao H., Liua Z., Verfaillie C., Zweier J., Gupta K., Liu Z. MAPK/ERK signaling mediates VEGF-induced bone marrow stem cell differentiation into endothelial cell. Journal of Cellular & Molecular Medicine. 2008 ; 12: 2395-406